{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:04:13Z","timestamp":1762542253326},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\u2018Phylogenetic trees\u2019 are commonly used for the analysis of chemogenomics datasets and to relate protein targets to each other, based on the (shared) bioactivities of their ligands. However, no real assessment as to the suitability of this representation has been performed yet in this area. We aimed to address this shortcoming in the current work, as exemplified by a kinase data set, given the importance of kinases in many diseases as well as the availability of large-scale datasets for analysis. In this work, we analyzed a dataset comprising 157 compounds, which have been tested at concentrations of 1\u00a0\u03bcM and 10\u00a0\u03bcM against a panel of 225 human protein kinases in full-matrix experiments, aiming to explain kinase promiscuity and selectivity against inhibitors. Compounds were described by chemical features, which were used to represent kinases (<jats:italic>i.e.<\/jats:italic> each kinase had an active set of features and an inactive set).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using this representation, a bioactivity-based classification was made of the kinome, which partially resembles previous sequence-based classifications, where particularly kinases from the TK, CDK, CLK and AGC branches cluster together. However, we were also able to show that in approximately 57% of cases, on average 6 kinase inhibitors exhibit activity against kinases which are located at a large distance in the sequence-based classification (at a relative distance of 0.6 \u2013 0.8 on a scale from 0 to 1), but are correctly located closer to each other in our bioactivity-based tree (distance 0 \u2013 0.4). Despite this improvement on sequence-based classification, also the bioactivity-based classification needed further attention: for approximately 80% of all analyzed kinases, kinases classified as neighbors according to the bioactivity-based classification also show high SAR similarity (<jats:italic>i.e.<\/jats:italic> a high fraction of shared active compounds and therefore, interaction with similar inhibitors). However, in the remaining ~20% of cases a clear relationship between kinase bioactivity profile similarity and shared active compounds <jats:italic>could not<\/jats:italic> be established, which is in agreement with previously published atypical SAR (such as for LCK, FGFR1, AKT2, DAPK1, TGFR1, MK12 and AKT1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this work we were hence able to show that (1) targets (here kinases) with few shared activities are difficult to establish neighborhood relationships for, and (2) phylogenetic tree representations make implicit assumptions (<jats:italic>i.e.<\/jats:italic> that neighboring kinases exhibit similar interaction profiles with inhibitors) that are not always suitable for analyses of bioactivity space. While both points have been implicitly alluded to before, this is to the information of the authors the first study that explores both points on a comprehensive basis. Excluding kinases with few shared activities improved the situation greatly (the percentage of kinases for which no neighborhood relationship could be established dropped from 20% to only 4%). We can conclude that all of the above findings need to be taken into account when performing chemogenomics analyses, also for other target classes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1758-2946-5-49","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T10:01:27Z","timestamp":1386928887000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases"],"prefix":"10.1186","volume":"5","author":[{"given":"Shardul","family":"Paricharak","sequence":"first","affiliation":[]},{"given":"Tom","family":"Klenka","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Augustin","sequence":"additional","affiliation":[]},{"given":"Umesh A","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Bender","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"648_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/jm0608107","volume":"50","author":"JJ-L Liao","year":"2007","unstructured":"Liao JJ-L: Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem. 2007, 50: 409-424. 10.1021\/jm0608107.","journal-title":"J Med Chem"},{"key":"648_CR2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","volume":"9","author":"SK Hanks","year":"1995","unstructured":"Hanks SK, Hunter T: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995, 9: 576-596.","journal-title":"FASEB J"},{"key":"648_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, L\u00e9lias J-M, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005, 23: 329-336. 10.1038\/nbt1068.","journal-title":"Nat Biotechnol"},{"key":"648_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev.pharmtox.42.083001.144616","volume":"42","author":"Z Zhang","year":"2002","unstructured":"Zhang Z: Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002, 42: 209-234. 10.1146\/annurev.pharmtox.42.083001.144616.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"648_CR5","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (80-. ). 2002, 298: 1912-1934. 10.1126\/science.1075762.","journal-title":"Science (80-. )"},{"key":"648_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/gb-2003-4-5-111","volume":"4","author":"SK Hanks","year":"2003","unstructured":"Hanks SK: Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. 2003, 4: 111-10.1186\/gb-2003-4-5-111.","journal-title":"Genome Biol"},{"key":"648_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cbic.200500034","volume":"6","author":"H Weinmann","year":"2005","unstructured":"Weinmann H, Metternich R: Drug discovery process for kinase inhibitors. Chembiochem. 2005, 6: 455-459. 10.1002\/cbic.200500034.","journal-title":"Chembiochem"},{"key":"648_CR8","first-page":"1972","volume":"9","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R: Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003, 9: 1972-1979.","journal-title":"Clin Cancer Res"},{"key":"648_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cncr.11520","volume":"98","author":"G Garcia-Manero","year":"2003","unstructured":"Garcia-Manero G, Faderl S, O\u2019Brien S, Cortes J, Talpaz M, Kantarjian HM: Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003, 98: 437-457. 10.1002\/cncr.11520.","journal-title":"Cancer"},{"key":"648_CR10","first-page":"579","volume":"128","author":"H Koskela","year":"2012","unstructured":"Koskela H, Koskenvesa P, Mustjoki S, Porkka K: Current therapy of chronic myeloid leukemia. Duodecim. 2012, 128: 579-588.","journal-title":"Duodecim"},{"key":"648_CR11","doi-asserted-by":"publisher","first-page":"1209.e5","DOI":"10.1016\/j.urology.2007.03.029","volume":"69","author":"C Arce-Lara","year":"2007","unstructured":"Arce-Lara C, Shah MH, Jimenez RE, Patel VR, Benson DM, Clinton SK, Monk JP: Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach. Urology. 2007, 69: 1209.e5-1209.e7.","journal-title":"Urology"},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/11595000-000000000-00000","volume":"30","author":"M Bongers","year":"2012","unstructured":"Bongers M, Coup\u00e9 VMh, Jansma E, Smit E, Uyl-de-Groot CA: Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 2012, 30: 17-34. 10.2165\/11595000-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"648_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","volume":"17","author":"B Rexer","year":"2012","unstructured":"Rexer B, Arteaga C: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012, 17: 1-16. 10.1615\/CritRevOncog.v17.i1.20.","journal-title":"Crit Rev Oncog"},{"key":"648_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nchembio.530","volume":"7","author":"JT Metz","year":"2011","unstructured":"Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ: Navigating the kinome. Nat Chem Biol. 2011, 7: 200-202. 10.1038\/nchembio.530.","journal-title":"Nat Chem Biol"},{"key":"648_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nbt1228","volume":"24","author":"GV Paolini","year":"2006","unstructured":"Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL: Global mapping of pharmacological space. Nat Biotechnol. 2006, 24: 805-815. 10.1038\/nbt1228.","journal-title":"Nat Biotechnol"},{"issue":"Suppl 1","key":"648_CR16","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.leukres.2003.10.003","volume":"28","author":"GW Krystal","year":"2004","unstructured":"Krystal GW: Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res. 2004, 28 (Suppl 1): S53-S59.","journal-title":"Leuk Res"},{"key":"648_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nchembio.985","volume":"8","author":"A Donner","year":"2012","unstructured":"Donner A: Stem cells: Imatinib gets beta. Nat Chem Biol. 2012, 8: 502-","journal-title":"Nat Chem Biol"},{"key":"648_CR18","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2169\/internalmedicine.50.5903","volume":"50","author":"T Nagano","year":"2011","unstructured":"Nagano T, Kotani Y, Kobayashi K, Hatakeyama Y, Hori S, Kasai D, Funada Y, Nishimura H, Kondoh T, Nishimura Y: Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status. Intern Med. 2011, 50: 3019-3022. 10.2169\/internalmedicine.50.5903.","journal-title":"Intern Med"},{"key":"648_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/bjc.2011.516","volume":"106","author":"RY Tsang","year":"2012","unstructured":"Tsang RY, Finn RS: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012, 106: 6-13. 10.1038\/bjc.2011.516.","journal-title":"Br J Cancer"},{"key":"648_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc2787","volume":"10","author":"ZA Knight","year":"2010","unstructured":"Knight ZA, Lin H, Shokat KM: Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010, 10: 130-137. 10.1038\/nrc2787.","journal-title":"Nat Rev Cancer"},{"key":"648_CR21","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.1021\/jm8011036","volume":"51","author":"P Bamborough","year":"2008","unstructured":"Bamborough P, Drewry D, Harper G, Smith GK, Schneider K: Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem. 2008, 51: 7898-7914. 10.1021\/jm8011036.","journal-title":"J Med Chem"},{"key":"648_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbapap.2003.11.028","volume":"1697","author":"M Vieth","year":"2004","unstructured":"Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H: Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta. 2004, 1697: 243-257. 10.1016\/j.bbapap.2003.11.028.","journal-title":"Biochim Biophys Acta"},{"key":"648_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1359-6446(05)03477-X","volume":"10","author":"M Vieth","year":"2005","unstructured":"Vieth M, Sutherland JJ, Robertson DH, Campbell RM: Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today. 2005, 10: 839-846. 10.1016\/S1359-6446(05)03477-X.","journal-title":"Drug Discov Today"},{"key":"648_CR24","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2174\/156802611796391230","volume":"11","author":"E Van der Horst","year":"2011","unstructured":"Van der Horst E, Peironcely JE, Van Westen GJP, Van den Hoven OO, Galloway WRJD, Spring DR, Wegner JK, Van Vlijmen HWT, IJzerman AP, Overington JP, Bender A: Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr Top Med Chem. 2011, 11: 1964-1977. 10.2174\/156802611796391230.","journal-title":"Curr Top Med Chem"},{"key":"648_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/1471-2105-11-316","volume":"11","author":"E Van der Horst","year":"2010","unstructured":"Van der Horst E, Peironcely JE, IJzerman AP, Beukers MW, Lane JR, Van Vlijmen HWT, Emmerich MTM, Okuno Y, Bender A: A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinforma. 2010, 11: 316-10.1186\/1471-2105-11-316.","journal-title":"BMC Bioinforma"},{"key":"648_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2174\/138620707782507313","volume":"10","author":"A Bender","year":"2007","unstructured":"Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, Clemens PA, Davies JW: Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen. 2007, 10: 719-731. 10.2174\/138620707782507313.","journal-title":"Comb Chem High Throughput Screen"},{"key":"648_CR27","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1016\/j.bmc.2012.02.034","volume":"20","author":"E Lounkine","year":"2012","unstructured":"Lounkine E, Kutchukian P, Petrone P, Davies JW, Glick M: Chemotography for multi-target SAR analysis in the context of biological pathways. Bioorg Med Chem. 2012, 20: 5416-5427. 10.1016\/j.bmc.2012.02.034.","journal-title":"Bioorg Med Chem"},{"key":"648_CR28","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1039\/c2mb25110h","volume":"8","author":"F Cheng","year":"2012","unstructured":"Cheng F, Zhou Y, Li J, Li W, Liu G, Tang Y: Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst. 2012, 8: 2373-2384. 10.1039\/c2mb25110h.","journal-title":"Mol Biosyst"},{"key":"648_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/0008-5472.CAN-09-3106","volume":"70","author":"ML Sos","year":"2010","unstructured":"Sos ML, Rode HB, Heynck S, Martin P, Fischer F, Kl\u00fcter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010, 70: 868-874. 10.1158\/0008-5472.CAN-09-3106.","journal-title":"Cancer Res"},{"key":"648_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008, 26: 127-132. 10.1038\/nbt1358.","journal-title":"Nat Biotechnol"},{"key":"648_CR31","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen M-L, Wityak J, Borzilleri RM: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004, 47: 6658-6661. 10.1021\/jm049486a.","journal-title":"J Med Chem"},{"key":"648_CR32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cmdc.200700075","volume":"2","author":"D Kuhn","year":"2007","unstructured":"Kuhn D, Weskamp N, H\u00fcllermeier E, Klebe G: Functional classification of protein kinase binding sites using Cavbase. ChemMedChem. 2007, 2: 1432-1447. 10.1002\/cmdc.200700075.","journal-title":"ChemMedChem"},{"key":"648_CR33","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1021\/ci1001263","volume":"50","author":"F Milletti","year":"2010","unstructured":"Milletti F, Vulpetti A: Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model. 2010, 50: 1418-1431. 10.1021\/ci1001263.","journal-title":"J Chem Inf Model"},{"key":"648_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1021\/ci200314j","volume":"52","author":"E Martin","year":"2012","unstructured":"Martin E, Mukherjee P: Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. J Chem Inf Model. 2012, 52: 156-170. 10.1021\/ci200314j.","journal-title":"J Chem Inf Model"},{"key":"648_CR35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP: Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011, 29: 1046-1051. 10.1038\/nbt.1990.","journal-title":"Nat Biotechnol"},{"key":"648_CR36","unstructured":"Inhibitor Libraries and Pathway Panels: http:\/\/www.emdmillipore.com\/life-science-research\/inhibitor-libraries-and-pathway-panels\/c_bKSb.s1O9nQAAAEitTV5hDHD?\/p_uuid (accessed Oct 16, 2012)"},{"key":"648_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1042\/BJ20121418","volume":"451","author":"Y Gao","year":"2013","unstructured":"Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J. 2013, 451: 313-328. 10.1042\/BJ20121418.","journal-title":"Biochem J"},{"key":"648_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011, 29: 1039-1045. 10.1038\/nbt.2017.","journal-title":"Nat Biotechnol"},{"key":"648_CR39","first-page":"327","volume":"11","author":"A Bender","year":"2008","unstructured":"Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill W, Popov M, Jacoby E, Glick M: Which aspects of HTS are emperically correlated with downstream success?. Curr Opin Drug Discov Devel. 2008, 11: 327-337.","journal-title":"Curr Opin Drug Discov Devel"},{"key":"648_CR40","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1021\/jm901443h","volume":"53","author":"F Zuccotto","year":"2010","unstructured":"Zuccotto F, Ardini E, Casale E, Angiolini M: Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation. J Med Chem. 2010, 53: 2681-2694. 10.1021\/jm901443h.","journal-title":"J Med Chem"},{"key":"648_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/minf.201100112","volume":"30","author":"T Kalliokoski","year":"2011","unstructured":"Kalliokoski T, Vulpetti A: Large-scale evaluation of CavBase for analyzing the polypharmacology of Kinase inhibitors. Mol Inf. 2011, 30: 923-925. 10.1002\/minf.201100112.","journal-title":"Mol Inf"},{"key":"648_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","volume":"53","author":"A Levitzki","year":"2013","unstructured":"Levitzki A: Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013, 53: 161-185. 10.1146\/annurev-pharmtox-011112-140341.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"648_CR43","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1021\/jm800867g","volume":"51","author":"M Wawer","year":"2008","unstructured":"Wawer M, Peltason L, Weskamp N, Teckentrup A, Bajorath J: Structure-activity relationship anatomy by network-like similarity graphs and local structure-activity relationship indices. J Med Chem. 2008, 51: 6075-6084. 10.1021\/jm800867g.","journal-title":"J Med Chem"},{"key":"648_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tips.2012.03.005","volume":"33","author":"RA Norman","year":"2012","unstructured":"Norman RA, Toader D, Ferguson AD: Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci. 2012, 33: 273-278. 10.1016\/j.tips.2012.03.005.","journal-title":"Trends Pharmacol Sci"},{"key":"648_CR45","unstructured":"Merck Millipore KinaseProfiler Service Assay Protocols: http:\/\/www.millipore.com\/techpublications\/tech1\/pf3036 (accessed Oct 27, 2012)"},{"key":"648_CR46","unstructured":"Chemical Computing Group Inc: Molecular Operating Environment (MOE). http:\/\/www.chemcomp.com\/software.htm (accessed Oct 27, 2012)"},{"key":"648_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M: Extended-connectivity fingerprints. J Chem Inf Model. 2010, 50: 742-754. 10.1021\/ci100050t.","journal-title":"J Chem Inf Model"},{"key":"648_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/ci800249s","volume":"49","author":"A Bender","year":"2009","unstructured":"Bender A, Jenkins JL, Scheiber J, Sukuru SCK, Glick M, Davies JW: How similar are similarity searching methods? A principal component analysis of molecular descriptor space. J Chem Inf Model. 2009, 49: 108-119. 10.1021\/ci800249s.","journal-title":"J Chem Inf Model"},{"key":"648_CR49","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1021\/ci0498719","volume":"44","author":"A Bender","year":"2004","unstructured":"Bender A, Mussa HY, Glen RC: Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J Chem Inf Model. 2004, 44: 1708-1718. 10.1021\/ci0498719.","journal-title":"J Chem Inf Model"},{"key":"648_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1758-2946-3-3","volume":"3","author":"G Hinselmann","year":"2011","unstructured":"Hinselmann G, Rosenbaum L, Jahn A, Fechner N, Zell A: jCompoundMapper: an open source Java library and command-line tool for chemical fingerprints. J Cheminform. 2011, 3: 3-10.1186\/1758-2946-3-3.","journal-title":"J Cheminform"},{"key":"648_CR51","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1021\/jm701399f","volume":"51","author":"JJ Sutherland","year":"2008","unstructured":"Sutherland JJ, Higgs RE, Watson I, Vieth M: Chemical fragments as foundations for understanding target space and activity prediction. J Med Chem. 2008, 51: 2689-2700. 10.1021\/jm701399f.","journal-title":"J Med Chem"},{"key":"648_CR52","doi-asserted-by":"publisher","first-page":"W573","DOI":"10.1093\/nar\/gks485","volume":"40","author":"B Alix","year":"2012","unstructured":"Alix B, Boubacar DA, Vladimir M: T-REX: a web server for inferring, validating and visualizing phylogenetic trees and networks. Nucleic Acids Res. 2012, 40: W573-W579. 10.1093\/nar\/gks485.","journal-title":"Nucleic Acids Res"},{"key":"648_CR53","unstructured":"The Human Kinome: http:\/\/kinase.com\/human\/kinome\/ (accessed Oct 27, 2012)"},{"key":"648_CR54","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/molbev\/msr121","volume":"28","author":"K Tamura","year":"2011","unstructured":"Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011, 28: 2731-2739. 10.1093\/molbev\/msr121.","journal-title":"Mol Biol Evol"},{"key":"648_CR55","first-page":"164","volume":"5","author":"J Felsenstein","year":"1989","unstructured":"Felsenstein J: PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics. 1989, 5: 164-166.","journal-title":"Cladistics"},{"key":"648_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/bioinformatics\/btl529","volume":"23","author":"I Letunic","year":"2007","unstructured":"Letunic I, Bork P: Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics. 2007, 23: 127-128. 10.1093\/bioinformatics\/btl529.","journal-title":"Bioinformatics"},{"key":"648_CR57","unstructured":"Zmasek CM: Archaeopteryx: Visualization, Analysis, and Editing of Phylogenetic Trees. http:\/\/www.phylosoft.org\/archaeopteryx\/ (accessed 25 July, 2012)"},{"key":"648_CR58","doi-asserted-by":"publisher","first-page":"W475","DOI":"10.1093\/nar\/gkr201","volume":"39","author":"I Letunic","year":"2011","unstructured":"Letunic I, Bork P: Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res. 2011, 39: W475-W478. 10.1093\/nar\/gkr201.","journal-title":"Nucleic Acids Res"},{"key":"648_CR59","doi-asserted-by":"crossref","unstructured":"Merck Millipore DART: http:\/\/www.millipore.com\/life_sciences\/flx4\/dart (accessed Oct 27, 2012)","DOI":"10.1016\/S0958-2118(12)70009-5"},{"key":"648_CR60","first-page":"328","volume":"170","author":"RB Dessau","year":"2008","unstructured":"Dessau RB, Pipper CB: \u201cR\u201d\u2013project for statistical computing. Ugeskr Laeger. 2008, 170: 328-330.","journal-title":"Ugeskr Laeger"},{"key":"648_CR61","unstructured":"Orange Canvas: http:\/\/orange.biolab.si\/ (accessed Oct 27, 2012)"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1758-2946-5-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1758-2946-5-49\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1758-2946-5-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:00:49Z","timestamp":1630612849000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/1758-2946-5-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/1758-2946-5-49","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"13 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}